Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Opsens Inc T.OPS

Alternate Symbol(s):  OPSSF

OpSens Inc. is engaged in physiological measurements such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and in transcatheter aortic valve replacement (TAVR) in the structural heart market. The Company supplies an optical-based pressure guidewire (OptoWire), a guidewire used in the TAVR procedure (SavvyWire) and a wide range of miniature optical sensors to measure pressure and temperature to be used in a wide range of applications that can be integrated into other medical devices.


Recent & Breaking News (TSX:OPS)

OPSENS ANNOUNCES FIRST SAVVYWIRE(TM) PROCEDURE IN NEW ZEALAND

Canada NewsWire 5 hours ago

OPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS

Canada NewsWire 7 days ago

OPSENS TO HOST FOURTH QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL AND YEAR-END UPDATE ON NOVEMBER 22, 2022

Canada NewsWire 13 days ago

OPSENS ANNOUNCES DEPARTURE OF CFO

Canada NewsWire November 1, 2022

OpSens (TSX:OPS) announces first SavvyWire clinical cases in Europe

Trevor Abes  October 26, 2022

OPSENS ANNOUNCES FIRST SAVVYWIRE CLINICAL CASES IN EUROPE AND LAUNCH OF SAFE-TAVI STUDY

Canada NewsWire October 26, 2022

OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

Trevor Abes  September 23, 2022

OPSENS ANNOUNCES FIRST SAVVYWIRE PROCEDURE IN THE UNITED STATES BY DR. PHILIPPE GENEREUX OF MORRISTOWN MEDICAL CENTER

Canada NewsWire September 23, 2022

OPSENS ANNOUNCES FDA CLEARANCE FOR THE SAVVYWIRE(TM) FOR USE IN TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) PROCEDURES

Canada NewsWire September 15, 2022

OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in Boston September 16-19, 2022

Canada NewsWire September 14, 2022

OPSENS ANNOUNCES THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS WITH RECORD QUARTERLY REVENUES

Canada NewsWire July 14, 2022

OpSens (TSX:OPS) awarded diagnostics agreement

Caroline Egan  July 11, 2022

OpSens Awarded Interventional Specialty Diagnostics Agreement with Premier for OptoWire III

Canada NewsWire July 11, 2022

OPSENS TO HOST THIRD QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, JULY 14

Canada NewsWire July 7, 2022

OPSENS ANNOUNCES GLOBAL SAVVYWIRE(TM) FIRST COMMERCIAL USE

Canada NewsWire June 7, 2022

OPSENS SAVVYWIRE(TM) FIRST-IN-HUMAN RESULTS PRESENTED AT EUROPCR IN PARIS AND SIMULTANEOUSLY PUBLISHED IN EUROINTERVENTION JOURNAL

Canada NewsWire May 19, 2022

OPSENS ANNOUNCES PUBLICATION IN JSCAI OF DATA SUPPORTING THE CORRELATION BETWEEN THE OPTOWIRE AND A NOVEL TAVR INTERFACE WITH STANDARD OF CARE, BEFORE AND AFTER TAVR

Canada NewsWire May 18, 2022

OPSENS ANNOUNCES HEALTH CANADA APPROVAL FOR ITS NEW TAVR GUIDEWIRE

Canada NewsWire April 26, 2022

OPSENS ANNOUNCES SECOND QUARTER FISCAL 2022 FINANCIAL RESULTS

Canada NewsWire April 13, 2022

OPSENS TO HOST SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON WEDNESDAY, APRIL 13

Canada NewsWire April 6, 2022